Drug Substance To Fill-Finish Handoff: What Sponsors Need To Know

The transition of drug substance to fill-finish manufacturing is a critical and often complex phase in drug development, requiring coordination across multiple stakeholders. In early and mid-stage programs, limited batch history and evolving product understanding can introduce uncertainty, making proactive planning essential. When drug substance and fill-finish activities are managed by separate organizations, risks related to misaligned timelines, communication gaps, and unclear expectations can significantly impact progress and product quality. Early engagement with the fill-finish partner allows for a deeper understanding of product behavior, enabling better process design and risk mitigation before cGMP manufacturing begins. Equally important is ensuring proper documentation, material readiness, and clearly defined quality responsibilities across all parties. By prioritizing transparency, collaboration, and early technical involvement, sponsors can strengthen handoff efficiency, minimize delays, and support consistent, high-quality manufacturing outcomes throughout development and into commercialization.